Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Win McNamee/Getty Images

Facebook on Tuesday removed a post from President Trump in which he falsely claimed that COVID-19 is less deadly "in most populations" than the flu. Twitter labeled the tweet for violating its rules about "spreading misleading and potentially harmful information," but left it up because it may be "in the public's interest."

Why it matters: Facebook has been criticized for not removing posts that violate community guidelines in a timely manner, yet the company sprung to action when Trump posted misinformation about the virus that "could contribute to imminent physical harm." Twitter took action about 30 minutes later.

What they're saying:

  • A Facebook spokesperson told Axios: “We remove incorrect information about the severity of COVID-19, and have now removed this post."
  • A Twitter spokesperson told Axios: We placed a public interest notice on this Tweet for violating our COVID-19 Misleading Information Policy by making misleading health claims about COVID-19. As is standard with this public interest notice, engagements with the Tweet will be significantly limited."

The backdrop: Trump, who is still battling COVID-19 and was hospitalized last week after a drop in his oxygen levels, tweeted, "Many people every year, sometimes over 100,000, and despite the Vaccine, die from the Flu. Are we going to close down our Country? No, we have learned to live with it, just like we are learning to live with Covid, in most populations far less lethal!!!"

  • The post echoed similar rhetoric the president had expressed back in March, when he tweeted: “So last year 37,000 Americans died from the common Flu. It averages between 27,000 and 70,000 per year. Nothing is shut down, life & the economy go on. At this moment there are 546 confirmed cases of CoronaVirus, with 22 deaths. Think about that!”

The bottom line: The coronavirus has now killed over 210,000 Americans. Trump has been criticized for downplaying the severity of the pandemic, which he has continued to do even after his hospitalization and treatment with various experimental drugs.

Go deeper: With Trump's return, risks rise in the West Wing

Go deeper

Jan 14, 2021 - Health

Delays overshadow Johnson & Johnson vaccine's long-lasting potential

Photo: AaronP/Bauer-Griffin/GC Images via Getty

Participants who received Johnson & Johnson’s one-shot vaccine in an early study developed coronavirus immunity for at least 71 days, but a production lag could mean a rollout of fewer-than-promised doses, the New York Times reported Wednesday.

Why it matters: If approved, J&J’s vaccine would be the first available to protect from COVID with a single dose, streamlining vaccine administration and distribution.

Bryan Walsh, author of Future
Jan 13, 2021 - Health

Why COVID demands genetic surveillance

Illustration: Sarah Grillo/Axios

A seemingly more transmissible coronavirus variant is threatening the world — and exposing the U.S.' lackluster genetic surveillance.

Why it matters: A beefed-up program to sequence the genomes of infectious disease pathogens infections could help the U.S. identify dangerous new coronavirus variants — and get the jump on pathogens that could ignite the pandemics of the future.